# Evogene Ltd. (EVGN)

> Source: Nexqual · https://nexqual.com/EVGN · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Evogene Ltd. (EVGN), nexqual.com/EVGN" · informational, not investment advice.

**Price:** USD 0.38 (+1.48% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 0.37 · day 0.36–0.39 · 52w 0.35–1.33 · market cap $5.9M · NCM

## Key facts
- Insider open-market purchases, last ~7 months: 3 Form 4 filings, $693K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (1 analysts), mean target USD 2.15 (range 2.15–2.15).
- Total return with dividends: 1Y -69.3% vs S&P 500 +14.9%; 5Y -98.6% vs S&P 500 +80.3%.
- Next earnings: 2026-11-19, EPS estimate USD -0.19, revenue estimate $365K.

## Insider purchases (SEC Form 4, open-market, last ~7 months)
3 purchases, $693K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-08-11 | Recanati Leon | Director | 460,000 | $292K | 0.64 | Too little history (no open-market trades in 2023–2025) |
| 2026-08-04 | Recanati Leon | Director | 800,000 | $400K | 0.5 | Too little history (no open-market trades in 2023–2025) |
| 2026-06-04 | Tarcic Gabi | Chief Development Officer | 1,129 | $1K | 0.6 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 1 analysts; mean target USD 2.15 (low 2.15, high 2.15).

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | -69.3% | -98.6% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -69.5% | -57.4% |
| Volatility (annualized) | 79.1% | 70.4% |
| Max drawdown | -71.8% (Oct 2025→Oct 2026) | -98.6% (Nov 2021→Oct 2026) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 307.82 -2.21% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 90.9 +2.57% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.14 -3.28% · PRAX (Praxis Precision Medicines, Inc) USD 258.92 +0.96% · IONS (Ionis Pharmaceuticals, Inc.) USD 43.91 -0.81% · ABVX (Abivax SA) USD 90.23 -3.49%

## More
Full page: https://nexqual.com/EVGN · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in EVGN's own 20-F filed 2026-03-26 (https://www.sec.gov/Archives/edgar/data/1574565/000117891326001767/zk2634882.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Corteva, Inc. (CTVA) | "Under the terms of the collaboration agreement, AgPlenus and Corteva" |
| Partner | Alphabet (Google) (GOOGL) | "We completed our first collaboration with Google Cloud in mid-2025" |
| Partner | AgPlenus | "advance through development in our partners' pipelines, and to the extent that they are commercialized by AgPlenus' collaboration" |

Other companies that name EVGN in their own reports (relationship from EVGN's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| supplier | Bioceres Crop Solutions Corp. (BIOX) | 20-F 2025-11-10 | "Other companies such as Evogene Ltd., INARI and DBNBC also engage in trait discovery and licensing technology to customers." |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.19 | $-0.27 | -29.6% | $365,000 | 1 |
| Next quarter (ends 2026-12-31) | $-0.20 | $-0.27 | -25.9% | $390,000 | 1 |
| Current fiscal year (ends 2026-12-31) | $-1.10 | $-1.70 | -35.3% | $1.4M | 1 |
| Next fiscal year (ends 2027-12-31) | $-0.60 | $-0.80 | -25.0% | $2.6M | 1 |